{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T05:35:52Z","timestamp":1781242552948,"version":"3.54.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T00:00:00Z","timestamp":1617926400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T00:00:00Z","timestamp":1617926400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cancer patients with brain metastases (BMs) require multidisciplinary care, and treatment facility may play a role. This study aimed to investigate the impact of receiving treatment at academic centers on the overall survival (OS) of cancer patients with brain metastases (BMs) regardless of the primary cancer site.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective analysis of the National Cancer Database (NCDB) included patients diagnosed with non-small cell lung cancer, small-cell lung cancer, other types of lung cancer, breast cancer, melanoma, colorectal cancer, and kidney cancer and had brain metastases at the time of diagnosis. The data were extracted from the de-identified file of the NCDB, a joint program of the Commission on Cancer of the American College of Surgeons and the American Cancer Society. The Cox proportional hazard model adjusted for age at diagnosis, race, sex, place of living, income, education, primary tumor type, year of diagnosis, chemotherapy, radiation therapy (RT), and surgery of the primary cancer site was used to determine treatment facility-associated hazard ratios (HR) for survival. Overall survival was the primary outcome, which was analyzed with multivariable Cox proportional hazards regression modeling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 93,633 patients were analyzed, among whom 31,579\/93,633 (34.09%) were treated at academic centers. Based on the log-rank analysis, patients who received treatment at an academic facility had significantly improved OS (median OS:\u00a06.18, CI: 6.05\u20136.31 vs. 4.57, CI: 4.50\u20134.63\u00a0months;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) compared to patients who were treated at non-academic facilities. In the multivariable Cox regression analysis, receiving treatment at an academic facility was associated with significantly improved OS (HR: 0.85, CI: 0.84\u20130.87;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) compared to non-academic facility.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this extensive analysis of the NCDB, receiving treatment at academic centers was associated with significantly improved OS compared to treatment at non-academic centers.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-021-08129-4","type":"journal-article","created":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T06:03:40Z","timestamp":1617948220000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["The impact of treatment facility type on the survival of brain metastases patients regardless of the primary cancer type"],"prefix":"10.1186","volume":"21","author":[{"given":"Saber","family":"Amin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Baine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Meza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7279-0473","authenticated-orcid":false,"given":"Chi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,9]]},"reference":[{"issue":"25","key":"8129_CR1","doi-asserted-by":"publisher","first-page":"6207","DOI":"10.1200\/JCO.2005.03.145","volume":"23","author":"CJ Langer","year":"2005","unstructured":"Langer CJ, Mehta MP. Current management of brain metastases, with a focus on systemic options. J Clin Oncol. 2005;23(25):6207\u201319. https:\/\/doi.org\/10.1200\/JCO.2005.03.145.","journal-title":"J Clin Oncol"},{"issue":"1","key":"8129_CR2","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1093\/neuonc\/nou099","volume":"17","author":"JL Villano","year":"2015","unstructured":"Villano JL, Durbin EB, Normandeau C, Thakkar JP, Moirangthem V, Davis FG. Incidence of brain metastasis at initial presentation of lung cancer. Neuro-Oncology. 2015;17(1):122\u20138. https:\/\/doi.org\/10.1093\/neuonc\/nou099.","journal-title":"Neuro-Oncology"},{"issue":"19","key":"8129_CR3","doi-asserted-by":"publisher","first-page":"5805","DOI":"10.3748\/wjg.v21.i19.5805","volume":"21","author":"W Feng","year":"2015","unstructured":"Feng W, Zhang P, Zheng X, Chen M, Mao WM. Incidence and treatment of brain metastasis in patients with esophageal carcinoma. World J Gastroenterol. 2015;21(19):5805\u201312. https:\/\/doi.org\/10.3748\/wjg.v21.i19.5805.","journal-title":"World J Gastroenterol"},{"issue":"9","key":"8129_CR4","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1093\/neuonc\/nos152","volume":"14","author":"FG Davis","year":"2012","unstructured":"Davis FG, Dolecek TA, McCarthy BJ, Villano JL. Toward determining the lifetime occurrence of metastatic brain tumors estimated from 2007 United States cancer incidence data. Neuro-Oncology. 2012;14(9):1171\u20137. https:\/\/doi.org\/10.1093\/neuonc\/nos152.","journal-title":"Neuro-Oncology"},{"issue":"1","key":"8129_CR5","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s11912-011-0203-y","volume":"14","author":"L Nayak","year":"2012","unstructured":"Nayak L, Lee EQ, Wen PY. Epidemiology of brain metastases. Curr Oncol Rep. 2012;14(1):48\u201354. https:\/\/doi.org\/10.1007\/s11912-011-0203-y.","journal-title":"Curr Oncol Rep"},{"issue":"1","key":"8129_CR6","doi-asserted-by":"publisher","first-page":"5-018-0055-y","DOI":"10.1038\/s41572-018-0055-y","volume":"5","author":"AS Achrol","year":"2019","unstructured":"Achrol AS, Rennert RC, Anders C, et al. Brain metastases. Nat Rev Dis Primers. 2019;5(1):5-018-0055-y.","journal-title":"Nat Rev Dis Primers"},{"key":"8129_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/B978-0-12-811161-1.00001-3","volume":"149","author":"C Nolan","year":"2018","unstructured":"Nolan C, Deangelis LM. Overview of metastatic disease of the central nervous system. Handb Clin Neurol. 2018;149:3\u201323. https:\/\/doi.org\/10.1016\/B978-0-12-811161-1.00001-3.","journal-title":"Handb Clin Neurol"},{"issue":"4","key":"8129_CR8","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.clcc.2015.05.009","volume":"14","author":"M Michl","year":"2015","unstructured":"Michl M, Thurmaier J, Schubert-Fritschle G, Wiedemann M, Laubender RP, N\u00fcssler NC, et al. Brain metastasis in colorectal cancer patients: survival and analysis of prognostic factors. Clin Colorectal Cancer. 2015;14(4):281\u201390. https:\/\/doi.org\/10.1016\/j.clcc.2015.05.009.","journal-title":"Clin Colorectal Cancer"},{"key":"8129_CR9","doi-asserted-by":"publisher","first-page":"10-9966-30-10","DOI":"10.1186\/1756-9966-30-10","volume":"30","author":"A Fabi","year":"2011","unstructured":"Fabi A, Felici A, Metro G, et al. Brain metastases from solid tumors: Disease outcome according to type of treatment and therapeutic resources of the treating center. J Exp Clin Cancer Res. 2011;30:10-9966-30-10.","journal-title":"J Exp Clin Cancer Res"},{"issue":"7","key":"8129_CR10","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1111\/ijcp.12395","volume":"68","author":"M Esmaeilzadeh","year":"2014","unstructured":"Esmaeilzadeh M, Majlesara A, Faridar A, Hafezi M, Hong B, Esmaeilnia-Shirvani H, et al. Brain metastasis from gastrointestinal cancers: a systematic review. Int J Clin Pract. 2014;68(7):890\u20139. https:\/\/doi.org\/10.1111\/ijcp.12395.","journal-title":"Int J Clin Pract"},{"key":"8129_CR11","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3389\/fonc.2016.00049","volume":"6","author":"JV Cohen","year":"2016","unstructured":"Cohen JV, Kluger HM. Systemic immunotherapy for the treatment of brain metastases. Front Oncol. 2016;6:49.","journal-title":"Front Oncol"},{"issue":"2","key":"8129_CR12","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1200\/JCO.2010.30.1655","volume":"29","author":"M Kocher","year":"2011","unstructured":"Kocher M, Soffietti R, Abacioglu U, Vill\u00e0 S, Fauchon F, Baumert BG, et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol. 2011;29(2):134\u201341. https:\/\/doi.org\/10.1200\/JCO.2010.30.1655.","journal-title":"J Clin Oncol"},{"issue":"4","key":"8129_CR13","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1093\/annonc\/mds529","volume":"24","author":"YL Wu","year":"2013","unstructured":"Wu YL, Zhou C, Cheng Y, Lu S, Chen GY, Huang C, et al. Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803). Ann Oncol. 2013;24(4):993\u20139. https:\/\/doi.org\/10.1093\/annonc\/mds529.","journal-title":"Ann Oncol"},{"issue":"11","key":"8129_CR14","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/S1470-2045(12)70431-X","volume":"13","author":"GV Long","year":"2012","unstructured":"Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(11):1087\u201395. https:\/\/doi.org\/10.1016\/S1470-2045(12)70431-X.","journal-title":"Lancet Oncol"},{"issue":"7","key":"8129_CR15","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1038\/bjc.2012.346","volume":"107","author":"YS Yap","year":"2012","unstructured":"Yap YS, Cornelio GH, Devi BC, et al. Brain metastases in asian HER2-positive breast cancer patients: anti-HER2 treatments and their impact on survival. Br J Cancer. 2012;107(7):1075\u201382. https:\/\/doi.org\/10.1038\/bjc.2012.346.","journal-title":"Br J Cancer"},{"issue":"1","key":"8129_CR16","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1093\/annonc\/mdu486","volume":"26","author":"IE Krop","year":"2015","unstructured":"Krop IE, Lin NU, Blackwell K, Guardino E, Huober J, Lu M, et al. Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA. Ann Oncol. 2015;26(1):113\u20139. https:\/\/doi.org\/10.1093\/annonc\/mdu486.","journal-title":"Ann Oncol"},{"key":"8129_CR17","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.2147\/OTT.S52172","volume":"6","author":"Y Fan","year":"2013","unstructured":"Fan Y, Huang Z, Fang L, Miu L, Lin N, Gong L, et al. Chemotherapy and EGFR tyrosine kinase inhibitors for treatment of brain metastases from non-small-cell lung cancer: survival analysis in 210 patients. Onco Targets Ther. 2013;6:1789\u2013803. https:\/\/doi.org\/10.2147\/OTT.S52172.","journal-title":"Onco Targets Ther"},{"issue":"2","key":"8129_CR18","doi-asserted-by":"publisher","first-page":"227","DOI":"10.3171\/2012.5.JNS111929","volume":"117","author":"JP Knisely","year":"2012","unstructured":"Knisely JP, Yu JB, Flanigan J, Sznol M, Kluger HM, Chiang VL. Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. J Neurosurg. 2012;117(2):227\u201333. https:\/\/doi.org\/10.3171\/2012.5.JNS111929.","journal-title":"J Neurosurg"},{"issue":"5","key":"8129_CR19","doi-asserted-by":"publisher","first-page":"978","DOI":"10.3171\/2012.2.JNS111353","volume":"116","author":"DC Cochran","year":"2012","unstructured":"Cochran DC, Chan MD, Aklilu M, Lovato JF, Alphonse NK, Bourland JD, et al. The effect of targeted agents on outcomes in patients with brain metastases from renal cell carcinoma treated with gamma knife surgery. J Neurosurg. 2012;116(5):978\u201383. https:\/\/doi.org\/10.3171\/2012.2.JNS111353.","journal-title":"J Neurosurg"},{"issue":"2","key":"8129_CR20","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.ijrobp.2015.01.004","volume":"92","author":"AP Kiess","year":"2015","unstructured":"Kiess AP, Wolchok JD, Barker CA, Postow MA, Tabar V, Huse JT, et al. Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. Int J Radiat Oncol Biol Phys. 2015;92(2):368\u201375. https:\/\/doi.org\/10.1016\/j.ijrobp.2015.01.004.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"8129_CR21","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1470-2045(16)30053-5","volume":"17","author":"SB Goldberg","year":"2016","unstructured":"Goldberg SB, Gettinger SN, Mahajan A, Chiang AC, Herbst RS, Sznol M, et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2016;17(7):976\u201383. https:\/\/doi.org\/10.1016\/S1470-2045(16)30053-5.","journal-title":"Lancet Oncol."},{"issue":"8","key":"8129_CR22","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa1805453","volume":"379","author":"HA Tawbi","year":"2018","unstructured":"Tawbi HA, Forsyth PA, Algazi A, Hamid O, Hodi FS, Moschos SJ, et al. Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N Engl J Med. 2018;379(8):722\u201330. https:\/\/doi.org\/10.1056\/NEJMoa1805453.","journal-title":"N Engl J Med"},{"issue":"2","key":"8129_CR23","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.4031","volume":"11","author":"A Modh","year":"2019","unstructured":"Modh A, Doshi A, Burmeister C, Elshaikh MA, Lee I, Shah M. Disparities in the use of single-fraction stereotactic radiosurgery for the treatment of brain metastases from non-small cell lung cancer. Cureus. 2019;11(2):e4031. https:\/\/doi.org\/10.7759\/cureus.4031.","journal-title":"Cureus."},{"issue":"12","key":"8129_CR24","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1002\/hed.23498","volume":"36","author":"A Eskander","year":"2014","unstructured":"Eskander A, Merdad M, Irish JC, Hall SF, Groome PA, Freeman JL, et al. Volume-outcome associations in head and neck cancer treatment: a systematic review and meta-analysis. Head Neck. 2014;36(12):1820\u201334. https:\/\/doi.org\/10.1002\/hed.23498.","journal-title":"Head Neck"},{"issue":"1","key":"8129_CR25","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.19697","volume":"3","author":"RM Carey","year":"2020","unstructured":"Carey RM, Fathy R, Shah RR, Rajasekaran K, Cannady SB, Newman JG, et al. Association of type of treatment facility with overall survival after a diagnosis of head and neck cancer. JAMA Netw Open. 2020;3(1):e1919697. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.19697.","journal-title":"JAMA Netw Open"},{"issue":"6","key":"8129_CR26","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1002\/cam4.1070","volume":"6","author":"KS Mak","year":"2017","unstructured":"Mak KS, Agarwal A, Qureshi MM, Truong MT. Hypofractionated short-course radiotherapy in elderly patients with glioblastoma multiforme: an analysis of the national cancer database. Cancer Med. 2017;6(6):1192\u2013200. https:\/\/doi.org\/10.1002\/cam4.1070.","journal-title":"Cancer Med"},{"issue":"2","key":"8129_CR27","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s11060-016-2101-5","volume":"128","author":"R Rhome","year":"2016","unstructured":"Rhome R, Fisher R, Hormigo A, Parikh RR. Disparities in receipt of modern concurrent chemoradiotherapy in glioblastoma. J Neuro-Oncol. 2016;128(2):241\u201350. https:\/\/doi.org\/10.1007\/s11060-016-2101-5.","journal-title":"J Neuro-Oncol"},{"key":"8129_CR28","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jocn.2017.10.087","volume":"47","author":"A Hauser","year":"2018","unstructured":"Hauser A, Dutta SW, Showalter TN, Sheehan JP, Grover S, Trifiletti DM. Impact of academic facility type and volume on post-surgical outcomes following diagnosis of glioblastoma. J Clin Neurosci. 2018;47:103\u201310. https:\/\/doi.org\/10.1016\/j.jocn.2017.10.087.","journal-title":"J Clin Neurosci"},{"issue":"12","key":"8129_CR29","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.hpb.2017.04.017","volume":"19","author":"QD Chu","year":"2017","unstructured":"Chu QD, Zhou M, Peddi P, Medeiros KL, Zibari GB, Shokouh-Amiri H, et al. Influence of facility type on survival outcomes after pancreatectomy for pancreatic adenocarcinoma. HPB (Oxford). 2017;19(12):1046\u201357. https:\/\/doi.org\/10.1016\/j.hpb.2017.04.017.","journal-title":"HPB (Oxford)"},{"issue":"12","key":"8129_CR30","doi-asserted-by":"publisher","first-page":"4091","DOI":"10.1245\/s10434-019-07657-5","volume":"26","author":"GC Lee","year":"2019","unstructured":"Lee GC, Gamblin TC, Fong ZV, Ferrone CR, Goyal L, Lillemoe KD, et al. Facility type is associated with margin status and overall survival of patients with resected intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2019;26(12):4091\u20139. https:\/\/doi.org\/10.1245\/s10434-019-07657-5.","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"8129_CR31","doi-asserted-by":"publisher","first-page":"4915","DOI":"10.21873\/anticanres.11057","volume":"36","author":"S Master","year":"2016","unstructured":"Master S, Munker R, Shi Z, Mills G, Shi R. Insurance status and other non-biological factors predict outcomes in acute myelogenous leukemia: analysis of data from the national cancer database. Anticancer Res. 2016;36(9):4915\u201321. https:\/\/doi.org\/10.21873\/anticanres.11057.","journal-title":"Anticancer Res"},{"issue":"2","key":"8129_CR32","doi-asserted-by":"publisher","first-page":"205","DOI":"10.3233\/BLC-180163","volume":"4","author":"GD Lewis","year":"2018","unstructured":"Lewis GD, Haque W, Verma V, Butler EB, Teh BS. The role of adjuvant radiation therapy in locally advanced bladder cancer. Bladder Cancer. 2018;4(2):205\u201313. https:\/\/doi.org\/10.3233\/BLC-180163.","journal-title":"Bladder Cancer"},{"issue":"12","key":"8129_CR33","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1016\/j.jtho.2018.09.007","volume":"13","author":"S Ramalingam","year":"2018","unstructured":"Ramalingam S, Dinan MA, Crawford J. Survival comparison in patients with stage IV lung cancer in academic versus community centers in the United States. J Thorac Oncol. 2018;13(12):1842\u201350. https:\/\/doi.org\/10.1016\/j.jtho.2018.09.007.","journal-title":"J Thorac Oncol"},{"issue":"5","key":"8129_CR34","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1001\/jama.293.5.557","volume":"293","author":"SM Chang","year":"2005","unstructured":"Chang SM, Parney IF, Huang W, Anderson FA Jr, Asher AL, Bernstein M, et al. Patterns of care for adults with newly diagnosed malignant glioma. JAMA. 2005;293(5):557\u201364. https:\/\/doi.org\/10.1001\/jama.293.5.557.","journal-title":"JAMA."},{"issue":"8","key":"8129_CR35","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1002\/cncr.32666","volume":"126","author":"P Riviere","year":"2020","unstructured":"Riviere P, Luterstein E, Kumar A, Vitzthum LK, Deka R, Sarkar RR, et al. Survival of african american and non-hispanic white men with prostate cancer in an equal-access health care system. Cancer. 2020;126(8):1683\u201390. https:\/\/doi.org\/10.1002\/cncr.32666.","journal-title":"Cancer."},{"issue":"20","key":"8129_CR36","doi-asserted-by":"publisher","first-page":"2986","DOI":"10.1182\/bloodadvances.2019000308","volume":"3","author":"S Ailawadhi","year":"2019","unstructured":"Ailawadhi S, Parikh K, Abouzaid S, Zhou Z, Tang W, Clancy Z, et al. Racial disparities in treatment patterns and outcomes among patients with multiple myeloma: a SEER-medicare analysis. Blood Adv. 2019;3(20):2986\u201394. https:\/\/doi.org\/10.1182\/bloodadvances.2019000308.","journal-title":"Blood Adv"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08129-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-08129-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08129-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T06:12:05Z","timestamp":1617948725000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-08129-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,9]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["8129"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-08129-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-88060\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,9]]},"assertion":[{"value":"22 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study used data from the NCDB. The data is de-identified and holds no identifying patient information, and therefore, written informed consent was not needed for this study. The institutional review board (IRB) was also not required for the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"387"}}